NCT04575415

Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study

Bevacizumab Plus EGFR Tyrosine Kinase Inhibitors in Chinese Patients With Stage IIIB-IV EGFR-mutant Non-small Cell Lung Cancer: a Prospective,Multicenter, Non-interventional,Real-world Study

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 272 (estimated)
• Sponsor: Guangdong Association of Clinical Trials · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a prospective, multicenter, real-world study to investigate the efficacy and safety of bevacizumab plus epidermal growth factor (EGFR) Tyrosine Kinase Inhibitors in Chinese Patients With Stage IIIB/IV EGFR-mutant Non-small Cell Lung Cancer.

Conditions

• NSCLC

Interventions

Type	Name	Description
DRUG	Bevacizumab	Bevacizumab 15mg/kg or clinical routine dose by intravenous drip infusion on day 1 of a 21-day cycle
DRUG	Erlotinib	Erlotinib 150mg, orally once a day
DRUG	Gefitinib	Gefitinib 250mg, orally once a day
DRUG	Icotinib	Icotinib 125mg three times a day
DRUG	Afatinib	Afatinib 40 mg or clinical routine dose once daily
DRUG	Dacomitinib	Dacomitinib 45mg or clinical routine dose once daily
DRUG	Osimertinib	Osimertinib 80 mg once daily

Timeline

• Start date: 2020-10-07
• Primary completion: 2023-05-01
• Completion: 2023-12-01
• First posted: 2020-10-05
• Last updated: 2020-10-20

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study